A Phase II, Multi-center, Randomized, Double-blind, Parallel-group Study of the Safety and Efficacy of Different Lenalidomide (Revlimid) Dose Regimens in Subjects With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia
Interventional
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment
Safety [type, frequency, and severity of adverse events (AEs) and relationship of AEs to lenalidomide]
24 months post LPFV
Yes
Jay Mei, M.D.
Study Director
Celgene Corporation
United States: Food and Drug Administration
CC-5013-CLL-009
NCT00963105
July 2009
March 2013
Name | Location |
---|---|
Roswell Park Cancer Institute | Buffalo, New York 14263 |
Stanford University | Stanford, California 94305 |
Rush University Medical Center | Chicago, Illinois 60612-3824 |
Hackensack University Medical Center | Hackensack, New Jersey 07601 |
Indiana University Melvin and Bren Simon Cancer Center | Indianapolis, Indiana 46202-5289 |
The Cleveland Clinic Foundation | Cleveland, Ohio |
Karmanos Cancer Institute | Detroit, Michigan 48201 |
Wake Forest University School of Medicine | Winston-Salem, North Carolina 27157-1023 |
Desert Hematology Oncology Medical Group, Inc. | Rancho Mirage, California 92270 |
Cancer & Blood Disease Center | Lecanto, Florida 34461 |
Robert H. Lurie Comprehensive Cancer Center | Chicago, Illinois 60611 |
Cancer Center of Central Connecticut | Southington, Connecticut |
Moores Cancer Center | La Jolla, California 92093-0820 |
Gabrail Cancer Center Research | Canton, Ohio 44718 |
Long Island Jewish Medical Center Biomedical Research Alliance of NY (BRANY) | New Hyde Park, New York 11042 |
Drexel University, College of Medicine | Philadelphia, Pennsylvania 19102 |